You are here: Industry Insights > NanoFlu

News List

Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases prnasia
September 28, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced publication...
Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate worldpharmanews
May 11, 2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced data from a preclinical study of the company's combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate.
Novavax plans FDA filing after NanoFlu trumps Sanofi flu vaccine pharmatimes
March 27, 2020
Novavax has unveiled new Phase III data showing that its recombinant quadrivalent seasonal influenza vaccine candidate, NanoFlu, met all primary endpoints in adults aged 65 and older against Sanofi’s Fluzone Quadrivalent.
Novavax’s Nanoflu compares well to Fluzone Quadrivalent pharmaceutical-technology
March 26, 2020
US-based Novavax has published top-line Phase III data for its seasonal influenza vaccine Nanoflu in adults aged 65 and over.